Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Recbio Technology Co., Ltd. (2179.HK)
Taizhou, CN
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.20% | -5.20% | -8.67% | +5.33% | -15.66% | +18.50% | -44.50% | -64.25% | -81.23% | -81.23% | -81.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-07 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-54.1% Q4'25: -93.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+3.5% Q4'25: +30.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-5,484.8% Q4'25: -18,523.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-4,750.1% Q4'25: -14,574.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-59.3% Q4'25: -105.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+11.0% Q4'25: +29.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.31× Q4'25: -0.76× (vs Q4'23)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
30.38M
est: 40.37M (-24.8%)
|
27.01M
est: 25.36M (+6.5%)
|
12.40M
est: 12.40M (+0.0%)
|
509.45M
509.45M – 509.45M
+4,009.6% YoY
|
13.71M
13.71M – 13.71M
-97.3% YoY
|
| EBITDA |
-569.87M
est: -40.37M (-1,311.6%)
|
-523.97M
est: -25.36M (-1,965.9%)
|
-486.44M
est: -12.40M (-3,824.0%)
|
-509.45M
-509.45M – -509.45M
-4,009.6% YoY
|
-13.71M
-13.71M – -13.71M
+97.3% YoY
|
| EBIT |
-617.75M
est: -40.37M (-1,430.2%)
|
-571.85M
est: -25.36M (-2,154.6%)
|
-588.85M
est: -12.40M (-4,650.1%)
|
-509.45M
-509.45M – -509.45M
-4,009.6% YoY
|
-13.71M
-13.71M – -13.71M
+97.3% YoY
|
| Net Income |
-571.96M
est: -565.51M (-1.1%)
|
-562.39M
est: -626.63M (+10.3%)
|
-594.59M
est: -563.24M (-5.6%)
|
-507.34M
-507.34M – -507.34M
+9.9% YoY
|
-270.21M
-270.21M – -270.21M
+46.7% YoY
|
| SGA |
152.24M
est: 522.36M (-70.9%)
|
111.67M
est: 328.18M (-66.0%)
|
13.95M
est: 160.40M (-91.3%)
|
6.59B
6.59B – 6.59B
+4,009.6% YoY
|
177.44M
177.44M – 177.44M
-97.3% YoY
|
| EPS |
-1.19
est: -1.06 (-11.8%)
|
-1.16
est: -1.18 (+1.7%)
|
-1.12
est: -1.08 (-3.7%)
|
-0.96
-0.96 – -0.96
+11.5% YoY
|
-0.51
-0.51 – -0.51
+46.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yong Liu | Founder, Executive Director & GM | 2M | — |
| Jing Wang | Executive Director & Chief Quality Officer | 2M | female |
| Kunxue Hong | Chief Science Officer | 2M | — |
| Bu Li | Chief Human Resource Officer | 1M | male |
| Qifang Wei | Board Secretary, Joint Company Secretary & Executive Director | 307.1K | male |
| Ka Yan Suen | Joint Company Secretary | — | female |
| Lei Zhou | Finance controller | — | male |
| Mei Yee Yung FCIS | Joint Company Secretary | — | female |
| Yang Zhou | Chief Operating Officer | — | male |
| Hongjun Zhou | Vice General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2179.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
